Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Proprietary Blend of Five Live Probiotic Strains Shown to Help Reduce Severity and Frequency of Common, Occasional GI Symptoms* Now Rolling out to Major U.S. Retailers LAVAL, QC, April 8, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") today announced the U.S. launch of its novel daily over-the-counter probiotic supplement, ENVIVE™. ENVIVE™ is shown to help reduce the severity and frequency of five occasional gastrointestinal (GI) symptoms - diarrhea, constipation, gas, bloating and discomfort - and help strengthen and protect the digestive system by strengthening the gut barrier.

Bausch Health Launches ENVIVE™ Daily Probiotic Supplement

Bausch Health Companies Inc. said Wednesday it will reduce debt by another $100 million using cash from operations to redeem its outstanding 7.00% senior secured notes due in 2024. The company, the former Valeant, already redeemed $200 million aggregate principal amount of the bonds in March.

Bausch Health to reduce debt by $100 million using cash from operations

New OVD Offers Exceptional Corneal Protection, Visibility During Ophthalmic Surgery LAVAL, QC, April 7, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that the U.S. Food and Drug Administration (FDA) has approved ClearVisc™ dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery. "The ClearVisc™ dispersive OVD is the latest advancement in Bausch + Lomb's rich pipeline of ophthalmic surgical devices and is representative of our company's ongoing commitment to delivering innovations that fulfill the unmet needs of our customers," said Joe Gordon, U.S. president, Bausch + Lomb.

FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device

LAVAL, Quebec, March 31, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that it and certain of its affiliates have entered into a definitive agreement to sell all of their equity interests in Amoun Pharmaceutical Company S.A.E. ("Amoun") to Abu-Dhabi based ADQ (the "Purchaser"), one of the region's largest holding companies, for total gross consideration of approximately U.S. $740 million (including the assignment to the Purchaser of an intercompany loan granted by Bausch Health to Amoun), subject to certain adjustments.

Bausch Health Agrees To Sell Amoun Pharmaceuticals

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Why Is Bausch (BHC) Down 0.6% Since Last Earnings Report?

There are challenges to value creation in the proposed separation of Bausch Health Companies Inc's (NYSE: BHC) Bausch and Lomb (B&L) unit and RemainCo, which will be pharma-focused, according to BofA Securities. The Bausch Health Analyst: Jason Gerberry downgraded the rating for Bausch Health from Neutral to Underperform, while reducing the price target from $33 to $27.

Why Did BofA Downgrade Bausch Health?

Sam Eldessouky Will Succeed Paul S. Herendeen as Chief Financial Officer, Effective June 1, 2021 Herendeen Will Remain at Bausch Health as Advisor to the Chairman and CEO LAVAL, Quebec, March 11, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that Chief Financial Officer (CFO) Paul S.

Bausch Health Announces CFO Succession Plan

It depends on if you believe the troubled drugmaker can stage a comeback.

Is Bausch Health Companies a Good Stock to Buy Now?

Bausch Health Companies Inc. (BHC) CEO Joe Papa Presents at Barclays Global Healthcare Conference (Transcript)

LAVAL, Quebec, March 9, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") has published a presentation that Joseph C. Papa, chairman and CEO, Sam Eldessouky, senior vice president and corporate controller, and Arthur J. Shannon, senior...

Bausch Health Publishes Pipeline Update For The Barclays Global Healthcare Conference

Bausch Health Companies Inc. (BHC) Management Presents at J.P. Morgan Global High Yield & Leveraged Finance Conference (Transcript)

Cowen

Bausch Health's (BHC) CEO Joe Papa Presents at Cowen 41st Annual Health Care Conference (Transcript)

Anthem

DuPont de Nemours

Norfolk Southern

Takeda Pharmaceutical

Tenet Healthcare

Glenview Capital Management recently disclosed its portfolio updates for the fourth quarter of 2020, which ended on Dec. 31.

The Top New Buys of Larry Robbins' Firm

After a solid 2.4x rise from its March 2020 lows, at the current price of $31 per share, Bausch Health Companies' stock, best known for its contact lenses and branded generic drugs, appears to be fully valued. BHC stock has rallied from $13 to $31 off the March 2020 bottom compared to the S&P.

Should You Book Profits In Bausch Health Companies Stock After A Solid 2x Rally?

Bausch (BHC) reports better-than-expected results for the fourth quarter as the business shows recovery signs from the COVID-19 pandemic.

Bausch's (BHC) Q4 Earnings and Revenues Surpass Estimates

Bausch Health Companies Inc. (BHC) CEO Joe Papa on Q4 2020 Results - Earnings Call Transcript

Bausch Health Companies Inc (NYSE: BHC) is expanding its board of directors to accommodate two designees from activist investor Carl Icahn's Icahn Group, which owns 7.83% of the company's outstanding common stock. What Happened: The Quebec-based Bausch Health will add Brett Icahn and Steven Miller to its board in mid-March as independent directors, with each serving a term expiring at the company's 2021 annual meeting on April 27.

Bausch Health Adds 2 Directors Chosen By Carl Icahn: What Investors Need To Know

Bausch (BHC) delivered earnings and revenue surprises of 19.82% and -0.23%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Q4 Earnings Beat Estimates

Shares of Bausch Health Cos (NYSE:BHC) decreased 0.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 18.75% year over year to $1.33, which beat the estimate of $1.12.

Recap: Bausch Health Q4 Earnings

Bausch Health Companies Inc. reported Wednesday a narrower fourth-quarter net loss and revenue that declined from a year ago but topped expectations, as the COVID-19 pandemic led to "unprecedented challenges," but provided an upbeat full-year revenue outlook. The net loss was $153 million, or 43 cents a share, after a loss of $1.52 billion, or $4.30 a share, in the year-ago period.

Bausch Health reports narrower loss as revenue tops expectations, stock turns lower

Shares of Bausch Health Companies Inc. surged 2.9% toward a five-year high in premarket trading Wednesday, after the pharmaceuticals and medical devices company said it reached an agreement with billionaire activist investor Carl Icahn, and will add two of his nominees to its board of directors. The Icahn Group owns about 7.83% of the Bausch Health's shares outstanding.

Bausch Health stock surges toward 5-year high after agreement with activist investor Carl Icahn

Two New Directors to Be Appointed to Board Icahn to Support All Bausch Health Nominees for Election at 2021 Annual Meeting LAVAL, QB, Feb. 24, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") is pleased to announce that it will expand...

Bausch Health Announces Agreement With Carl C. Icahn

Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Bausch Health (BHC) Ahead of Earnings?

Bausch Health is significantly undervalued based on a sum of the parts analysis, DOMO Capital believes shares should be closer to $80 per share. Numerous well-known activists (Paulson & Co., ValueAct, Glenview, GoldenTree Asset Management, and Icahn) own approximately 30% of the shares outstanding.

Bausch Health: Valued Significantly Below Sum Of The Parts And Generating Activist Interest

Legendary fund manager and activist investor Carl Icahn accumulated a 7.8% stake in Bausch Health Companies Inc (NYSE: BHC) and will likely leverage his status as the company's largest shareholder to push for change. Icahn's stake Icahn disclosed a 27.8 million share position in Bausch Health, formerly known as Valeant Pharmaceuticals in early February.

News for Bausch Health Companies Inc Stock (BHC)